No. of Pages: 152 | Report Code: TIPRE00028620 | Category: Life Sciences
사우디아라비아에서 단클론 항체 기반 제품에 대한 수요는 임상 개발의 높은 성공률과 개발 1상에서 mAB에 대한 FDA 승인 확률이 ~14.1%로 보고되었으며 이는 저분자 약물 승인률(~7.6%)의 거의 두 배입니다. 반면, IAVI 보고서에 따르면 전 세계적으로 전염병이 시작되면서 많은 바이오제약 회사가 mAB 기반 제품을 저렴한 가격에 판매하고 있습니다. 예를 들어, 남아프리카에서 Roche는 자사의 유방암 mAB \"trastuzumab\"을 Herceptin의 오리지널 브랜드인 \"Hercelon\"이라는 두 번째 브랜드로 판매하고 있습니다. 그 외에도 이러한 mAB의 가용성이 제한되어 있기 때문에 다양한 제약 회사가 중간 소득 카운티에서 임상 시험을 수행하고 있습니다. 예를 들어, 머크는 남아프리카공화국, 콜롬비아, 말레이시아 등 여러 중간소득 국가에서 임상시험을 진행하고 있습니다. 이러한 요인들은 지역 시장에 긍정적인 영향을 미쳐 코로나19 팬데믹 속에서도 중동과 아프리카 지역에서 단클론항체의 채택률이 높아지고 있다.
새로운 기능과 기술을 통해 공급업체는 새로운 고객을 유치하고 신흥 시장에서 입지를 확장할 수 있습니다. 이 요인은 단일클론 항체 시장을 주도할 가능성이 높습니다. 중동 및 아프리카 단클론 항체 시장은 예측 기간 동안 양호한 CAGR로 성장할 것으로 예상됩니다.
Strategic insights for Middle East and Africa Monoclonal Antibodies involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 3,198.9 Million |
| Market Size by 2028 | US$ 5,741.1 Million |
| Global CAGR (2021 - 2028) | 8.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 출처
|
| Regions and Countries Covered | 중동 및 아프리카
|
| Market leaders and key company profiles |
The regional scope of Middle East and Africa Monoclonal Antibodies refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Middle East and Africa Monoclonal Antibodies Market is valued at US$ 3,198.9 Million in 2021, it is projected to reach US$ 5,741.1 Million by 2028.
As per our report Middle East and Africa Monoclonal Antibodies Market, the market size is valued at US$ 3,198.9 Million in 2021, projecting it to reach US$ 5,741.1 Million by 2028. This translates to a CAGR of approximately 8.7% during the forecast period.
The Middle East and Africa Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East and Africa Monoclonal Antibodies Market report:
The Middle East and Africa Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East and Africa Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East and Africa Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Middle East and Africa Monoclonal Antibodies Market
